Most of the clinics and retreats discussed in this guide sit hours from the nearest international hub. JetLuxe handles private charters with transparent pricing, verified operators, and the flexibility these itineraries usually demand — medical travel, multi-leg routes, last-minute changes, and discreet ground coordination.
Request a charter quotePsychedelic-assisted therapy (PAT) uses specific substances — most commonly psilocybin, sometimes MDMA, ayahuasca or ibogaine in different legal contexts — within a structured therapeutic protocol. The protocol matters as much as the substance: preparatory sessions establishing intent and assessing suitability, the dosing session itself with trained facilitators, and integration sessions afterward to translate the experience into durable behavioural or psychological change.
The category has had a rapid evolution. FDA Breakthrough Therapy designation for MDMA-assisted therapy for PTSD and psilocybin-assisted therapy for treatment-resistant depression catalysed serious clinical research. Oregon legalised supervised therapeutic psilocybin use through Measure 109 in 2020, with the first centres opening in 2023. Colorado followed in 2022 through Proposition 122. The Netherlands has long had de facto legal access to psilocybin-containing truffles (not mushrooms — the distinction matters legally). Jamaica's psilocybin-containing mushrooms have been legal throughout the modern regulatory period.
The growth in 2024-2026 has been substantial. Clinical interest, cultural normalisation through figures like Michael Pollan, and the real clinical data on treatment-resistant depression, PTSD and end-of-life distress have created consistent demand. The commercial category has grown in parallel, with varying clinical seriousness — hence the need for this guide.
Oregon operates a state-regulated system for supervised adult psilocybin use through licensed service centres. Services are available to adults 21+ through licensed facilitators in licensed service centres, with mandatory preparation, administration and integration sessions. Oregon does not require a medical diagnosis for access, though facilitators are trained to screen for contraindications. The system is regulated as a wellness service rather than a medical treatment; insurance does not cover it.
Colorado's regulatory framework came online in 2025, following a similar model to Oregon but with some differences in facilitator training requirements and service structure. Regulated adult access through licensed healing centres and facilitators. As in Oregon, not a medical system; self-pay.
Psilocybin-containing truffles (sclerotia) have a long-standing legal grey area in the Netherlands — they were not covered by the 2008 ban on psilocybin-containing fresh mushrooms, which left truffles legal. A mature retreat industry operates in this space with varying clinical seriousness. Psilocybin-containing mushrooms themselves remain illegal. The regulatory framework is looser than in Oregon or Colorado, which cuts both ways — more flexibility for well-run providers, less protection against poorly-run ones.
Psilocybin-containing mushrooms are not classified as controlled substances in Jamaica, which has enabled a retreat industry to develop legally since roughly 2016. Quality varies enormously — from clinically-structured programmes with trained Western therapists to lightly supervised experiences with minimal preparation or integration. The legal environment permits a wider range of protocols than the more tightly regulated US states.
Mexico has a de facto tolerated ayahuasca and psilocybin retreat industry operating in legal grey areas; quality is highly variable and some programmes use substances (ibogaine) that carry substantial medical risk. Peru, Brazil, and Costa Rica have long-established ayahuasca traditions operating in various legal frameworks. Switzerland has a limited compassionate-use programme for psilocybin-assisted therapy administered by trained psychiatrists, available to Swiss residents with specific clinical indications.
This guide focuses on the four jurisdictions with the clearest legal frameworks for retreat-style access: Oregon, Colorado, the Netherlands and Jamaica.
The evidence base is genuinely encouraging for specific indications but narrower than the mainstream cultural conversation often suggests. A defensible summary:
Treatment-resistant depression. Phase II clinical trials of psilocybin-assisted therapy have shown meaningful effect sizes in patients who have failed multiple standard antidepressants. Effects appear durable for months in a substantial subset of responders. The trials are not large and long-term safety data is limited; the effect is real but should not be oversold.
PTSD (MDMA-assisted). Phase III trial data led to the FDA Breakthrough Therapy designation, though FDA approval for clinical use of MDMA-assisted therapy has been through a regulatory back-and-forth. The evidence for sustained remission of PTSD symptoms is among the strongest in the category.
End-of-life existential distress. Small but consistent evidence that psilocybin-assisted therapy reduces anxiety and existential distress in patients with life-limiting illness. This is one of the more established indications.
Alcohol and substance use disorders. Promising but earlier-stage evidence, particularly for alcohol and nicotine. The structure of PAT (intensive sessions plus integration) is plausibly well-matched to the pattern-interruption needs of substance use disorders.
General wellness, creativity, self-development. This is the largest commercial use case and the least clinically evidenced. Subjective reports are often positive; outcome research in non-clinical populations is limited and confounded by self-selection. The honest view is that psychedelic experiences can be meaningful, but claims that they reliably produce durable benefit in asymptomatic populations outrun the evidence.
The retreats that market most aggressively toward the general-wellness category tend to be those least equipped with clinical screening and integration. The ones oriented toward diagnosed depression, PTSD, or specific therapeutic applications are usually better structured.
This section matters more than any other in the article. A serious retreat screens for these; a less serious one does not, and the consequences can be severe.
Psychiatric contraindications. Personal or strong family history of schizophrenia, schizoaffective disorder or bipolar I disorder is generally considered an absolute contraindication — the risk of precipitating a psychotic or manic episode is real and not hypothetical. Active psychosis, active mania, or recent severe suicidality are exclusions.
Cardiovascular contraindications. Uncontrolled hypertension, recent cardiac events, unstable cardiovascular disease — psilocybin and especially MDMA elevate heart rate and blood pressure; these situations are exclusions.
Medication interactions. SSRIs and SNRIs substantially reduce psilocybin effect and the intersection with serotonergic medications is complex — most retreats require tapering off these medications under medical supervision 2-6 weeks before a programme, which itself carries risks. MAOIs are an absolute interaction with many substances used in this category. Lithium combined with psilocybin has produced case reports of seizures. Stimulants, tricyclic antidepressants, and tramadol all warrant specific review. A proper retreat will review your medication list with a prescribing physician before confirming admission.
Pregnancy is an exclusion.
Substance use while in programme. Alcohol, recreational drug use, and even some supplements are contraindicated in the days around dosing sessions.
A growing number of licensed service centres operate in Oregon, with clinical seriousness varying. Centres affiliated with training programmes (for instance, some affiliated with the academic psychedelic research community) tend to run more rigorous preparation and integration protocols. Single sessions typically $2,500-$6,000 depending on dose, facilitator and centre; multi-session programmes cost proportionally more.
Colorado's regulated system came online in 2025 and is still maturing. Denver and Boulder have the highest density of licensed centres. Pricing is broadly in line with Oregon. The regulatory framework is similar but Colorado permits slightly different service models; research the specific centre carefully.
Synthesis has been among the most established Netherlands-based retreats, operating with clinical screening, trained facilitators and structured integration. Other well-regarded NL operators include Beckley and a handful of smaller providers. Netherlands retreats tend to run 3-4 days with one or two dosing sessions plus preparation and integration. Prices typically €2,500-€8,000 depending on programme.
MycoMeditations has been operating since around 2014 and runs multi-day programmes with licensed clinical staff and structured preparation and integration. Silo Wellness has a more luxury-oriented programme with similar clinical structure. Several smaller retreats operate with varying quality. Programmes typically 5-7 days with multiple dosing sessions.
Additional sources worth researching directly: MAPS (Multidisciplinary Association for Psychedelic Studies) maintains referral lists; the Oregon Health Authority and Colorado Department of Regulatory Agencies publish licensed facilitator and centre registries with verification. Neither substitutes for direct due diligence on any specific retreat.
A non-exhaustive list of when a psychedelic-assisted retreat is not appropriate:
The most medically sensitive preparation step is tapering any interacting medications. This must be done under the supervision of a prescribing physician. Coming off SSRIs quickly can produce discontinuation syndrome, depressive relapse, and sometimes complications severe enough to require medical intervention. The retreat will specify timing; your home physician manages the actual taper.
For Oregon and Colorado retreats, standard domestic US travel applies. For Netherlands retreats, Amsterdam is well-served by direct flights globally. Jamaica retreats typically provide arranged transfers from Montego Bay airport; GetTransfer handles the same routes at luxury tier if you prefer independent arrangement.
The retreat will provide specific guidance. Typically the stay includes simple meals, minimal phone use, and journaling materials. Sunscreen, comfortable clothing, and any critical personal medications are the practical items. Work devices and significant commercial responsibilities should be explicitly set aside for the duration.
Standard travel insurance rarely covers psychedelic-assisted services directly, but the travel itself is usually covered as normal. Medical incidents during the stay would typically be covered to the extent normal medical incidents in the country are. SafetyWing handles the baseline travel incident layer; some retreats carry specific indemnity insurance for the clinical programme itself — ask.
The integration phase is where the work actually consolidates. Most serious retreats include 2-4 post-retreat sessions; some offer longer-term integration coaching for additional cost. If you do not have access to integration support at home, choose a retreat that provides it. The experience without integration is often disorienting and occasionally counterproductive.
Psychedelic-assisted therapy in regulated jurisdictions is a legitimate category with meaningful evidence for specific indications and real but manageable risks if done properly. My framing for readers considering it:
If you have diagnosed treatment-resistant depression, PTSD, or end-of-life distress, the evidence base supports considering this as a structured clinical option, ideally in coordination with your treating clinicians. Oregon or Colorado licensed centres for US residents; Netherlands for European residents; Switzerland's compassionate-use programme for Swiss residents who meet criteria.
If you are a generally healthy person without a specific clinical goal, the evidence is weaker and the risks — while usually manageable with proper screening — are not zero. A thoughtful approach includes careful selection of a clinically structured provider (not a holiday-oriented one), genuine commitment to integration, and honest engagement with whether this is the right intervention for what you are actually trying to address.
If you have any psychotic or bipolar I spectrum history personal or familial, or any of the medical exclusions, the answer is simple: not this. Other therapeutic and wellness options are available and more appropriate.
The category is evolving rapidly. Regulatory frameworks are changing. Clinical evidence is accumulating. The quality range from best to worst provider is enormous. More than in any other category on this site, due diligence on the specific provider is the single most important decision. Do it carefully.
For readers considering this as part of a broader mental health and stress context, our executive burnout retreats guide covers the residential alternatives for serious clinical presentations. For readers whose underlying question is about sustained lifestyle and metabolic change rather than a single intensive experience, our sleep tourism and men's longevity guides may be more appropriate starting points.
Is this legal? Will I have problems back home?
The services discussed in this article operate within regulated or legally permitted frameworks in their respective jurisdictions. The substances themselves remain scheduled in most countries, including at the US federal level even as specific states permit regulated therapeutic use. Participating in legal services in the jurisdiction where they operate does not typically create legal exposure when you return home, but any metabolites in your system during subsequent drug testing (including at work or in custody situations) could theoretically produce problems. For most professional contexts the timeline of detection is short; for specific professions (aviation, military, some medical licensure contexts) the considerations are more complex and warrant specific legal advice.
Do I need to come off my antidepressants?
Usually yes, and this is the most medically sensitive part of the preparation. SSRIs and SNRIs substantially reduce psilocybin effect; the intersection is complex with other serotonergic medications. Most retreats require a supervised taper 2-6 weeks before programme entry. This taper carries its own risks — discontinuation syndrome, depressive relapse — and must be done with your prescribing physician, not managed remotely by the retreat. If you are unable or unwilling to taper, this is a signal that the timing is not right rather than a workaround you should try to negotiate.
What are the honest risks during the session itself?
The most common adverse events are acute anxiety, transient panic, nausea and physical discomfort during the experience. These are typically manageable with facilitator support and resolve as the substance wears off. More serious risks include acute psychotic symptoms (rare but serious, hence the psychiatric screening), sustained anxiety or disorientation in the days and weeks after (less rare, generally resolves with integration support), and rarely, persistent psychological distress that requires clinical intervention. Medical risks are generally low for properly screened participants but are not zero, particularly around cardiovascular response.
What's the difference between a clinical-style retreat and a ceremonial one?
Clinical-style retreats emphasise psychological screening, trained facilitators with therapeutic backgrounds, structured preparation and integration, and framing that supports psychological change. Ceremonial retreats (often using ayahuasca or traditional medicinal plants) emphasise traditional practice, cultural context, and often shaman-led or spiritual framing. Both can be serious and both can be unserious. The cultural framing matters less than the clinical safety features — screening, facilitator training, integration support, and crisis protocols. Readers without prior experience are generally better served by a clinical-style programme at least for the first engagement.
How much does integration matter — can I do this on holiday and go home?
Integration matters enormously. The experience itself is only the first half of the work; integration is where experiences translate into durable behavioural, relational or psychological change. Participants who treat the dosing session as the whole point and neglect integration commonly report that the experience faded quickly, sometimes leaving confusion or mild dysregulation without resolution. If you are not in a position to commit to the integration phase — either through the retreat's programme or through independent therapy afterward — the honest answer is that this is not the right time to do the retreat, regardless of how compelling the scheduling otherwise is.
Should I discuss this with my regular doctor or therapist?
Yes, in most cases. The medication review alone requires a prescribing physician's input; the tapering of any existing medication requires medical supervision. Your therapist, if you have one, is the right person to discuss whether the timing and context are appropriate and to support the integration phase afterwards. Some professionals are more comfortable with this conversation than others; if your current provider is dismissive, seeking a second opinion from a clinician with experience in the area may be useful. The conversation is legally and medically appropriate in jurisdictions where these services operate legally.
If you've read this far, you already know the ground logistics matter. JetLuxe — charter, jet card, empty-leg, all routed through one concierge.
Get a quoteWe use cookies to improve user experience. Choose what cookie categories you allow us to use. You can read more about our Cookie Policy by clicking on Cookie Policy below.
These cookies enable strictly necessary cookies for security, language support and verification of identity. These cookies can’t be disabled.
These cookies collect data to remember choices users make to improve and give a better user experience. Disabling can cause some parts of the site to not work properly.
These cookies help us to understand how visitors interact with our website, help us measure and analyze traffic to improve our service.
These cookies help us to better deliver marketing content and customized ads.